[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0213832A - Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma - Google Patents

Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma

Info

Publication number
BR0213832A
BR0213832A BR0213832-8A BR0213832A BR0213832A BR 0213832 A BR0213832 A BR 0213832A BR 0213832 A BR0213832 A BR 0213832A BR 0213832 A BR0213832 A BR 0213832A
Authority
BR
Brazil
Prior art keywords
fluorobenzamide
piperidino
dichlorophenyl
piperidin
oxo
Prior art date
Application number
BR0213832-8A
Other languages
English (en)
Inventor
Russell Bialecki
Cathy Dantzman
Keith Herzog
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0213832A publication Critical patent/BR0213832A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSTO, MéTODO PARA TRATAMENTO OU PREVENçãO DE BEXIGA SUPERATIVA OU INCONTINêNCIA URINáRIA EM UM INDIVìDUO, COMPOSIçãO FARMACêUTICA, E, USO DE (S)-N-[2-(3,4-DICLOROFENIL)-4-[4-(2-OXO-PIPERIDIN-1-IL)PIPERI DINO]BUTIL]-N-METIL-2-FLUOROBENZAMIDA OU UM SAL FARMACEUTICAMENTE ACEITáVEL DA MESMA". Os compostos de ligação a NK2R de acordo com o diagrama estrutural (I) utilizável para o tratamento ou prevenção de OAB ou UI em mamíferos, particularmente humanos, são descritos em que, nos referidos compostos D, A, R^ 1^, R^ 3^ e R^ 4^ são como definidos no relatório. Os sais farmaceuticamente vantajosos dos compostos, métodos de uso dos compostos, sozinhos ou em combinação com outros agentes farmacológicos, e composições farmacêuticas utilizáveis na prática dos métodos da invenção também são descritos.
BR0213832-8A 2001-11-02 2002-11-01 Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma BR0213832A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder
PCT/SE2002/001991 WO2003037889A1 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
BR0213832A true BR0213832A (pt) 2004-08-31

Family

ID=20285984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213832-8A BR0213832A (pt) 2001-11-02 2002-11-01 Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma

Country Status (16)

Country Link
US (1) US7368461B2 (pt)
EP (1) EP1444220B1 (pt)
JP (1) JP2005511571A (pt)
KR (1) KR20040053239A (pt)
CN (1) CN1610676A (pt)
AT (1) ATE353886T1 (pt)
BR (1) BR0213832A (pt)
CA (1) CA2465429A1 (pt)
DE (1) DE60218203T2 (pt)
ES (1) ES2282491T3 (pt)
IL (1) IL161600A0 (pt)
MX (1) MXPA04004075A (pt)
NO (1) NO20042138L (pt)
SE (1) SE0103795D0 (pt)
WO (1) WO2003037889A1 (pt)
ZA (1) ZA200403206B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CN112915266B (zh) * 2021-02-05 2021-11-09 武汉磁济科技有限公司 一种人工膀胱铁磁复合体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
EP1136472A4 (en) * 1998-12-04 2002-08-07 Viromax L L C ARYL- AND HETEROARYLAMIDES OF CARBOALCOXYSULFANILIC ACIDS
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
ZA200403206B (en) 2005-02-22
ES2282491T3 (es) 2007-10-16
ATE353886T1 (de) 2007-03-15
CA2465429A1 (en) 2003-05-08
DE60218203D1 (de) 2007-03-29
US20050203113A1 (en) 2005-09-15
US7368461B2 (en) 2008-05-06
WO2003037889A1 (en) 2003-05-08
DE60218203T2 (de) 2008-01-03
IL161600A0 (en) 2004-09-27
SE0103795D0 (sv) 2001-11-02
WO2003037889A8 (en) 2004-05-06
CN1610676A (zh) 2005-04-27
KR20040053239A (ko) 2004-06-23
MXPA04004075A (es) 2004-07-23
JP2005511571A (ja) 2005-04-28
EP1444220B1 (en) 2007-02-14
EP1444220A1 (en) 2004-08-11
NO20042138L (no) 2004-05-25

Similar Documents

Publication Publication Date Title
ATE224884T1 (de) Muscarin-antagonisten
NO20014479L (no) Fremgangsmåte ved behandling av spiseforstyrrelser
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
WO2002066450A3 (en) Anthrone derivatives and their use as ink inhibitors
BR0215158A (pt) Derivados de pirrolidina e piperidina como antagonistas de nk1
DE69631370D1 (de) Benzylpiperidine und -piperazine als muscarinantagonisten
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
CY1110798T1 (el) Συνδυασμοι περιλαμβανοντες αντιμουσκαρινικους παραγοντες και αναστολεις pde4
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
BR0213832A (pt) Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
GB0015246D0 (en) Method for the treatment of urinary incontinence
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
BR0213776A (pt) Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
BRPI0507802A (pt) composto, composição, e, método para tratar inflamação ou um distúrbio metabólico
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
BR0114609A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, e, método para o tratamento de depressão, ansiedade, obesidade ou incontinência urinária em um mamìfero.
WO2003042188A1 (fr) Derive de triazole, et composition medicamenteuse renfermant ce derive
WO2002044159A3 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
TH101946A (th) การรักษาอาการกลั้นปัสสาวะไม่อยู่
TH101946B (th) Treatment of urinary incontinence
MXPA01009463A (es) Tratamiento de hernia hiatial.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.